|Bid||24.780 x 68800|
|Ask||25.025 x 1500|
|Day's range||24.760 - 24.995|
|52-week range||16.480 - 25.580|
|PE ratio (TTM)||30.38|
|Earnings date||27 Jul 2017 - 31 Jul 2017|
|Dividend & yield||0.54 (1.91%)|
|1y target est||N/A|
BARCELONA, Spain, May 9, 2017 /PRNewswire/ -- Test is designed to detect the presence in whole blood, of the four clinically relevant species of Babesia ( B. microti, B. duncani, B. divergens, and B. ...
EMERYVILLE, Calif., April 24, 2017 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a global healthcare company with a history of more than 75 years of improving people's health and well-being and a leader in the development of innovative diagnostic solutions, announces that it has restated its 2005 agreement with OraSure Technologies ("OraSure"), a leader in point-of-care diagnostic tests. The test is FDA approved for qualitatively detecting hepatitis C virus antibodies in whole blood obtained through the use of a fingerstick or venipuncture.
Young blood loaded with a particular protein, which is less plentiful as people age, could rejuvenate learning and memory, Stanford University researchers said in a paper released today. It would take even longer to make drugs that mimic the protein. Ultimately, San Carlos' Alkahest Inc., which has rights to license the research, and Barcelona-based Grifols S.A. (GRFS) could market treatments aimed at age-associated declines in learning skills and memory, but not necessarily targeting memory-robbing Alzheimer's disease.